Li Q, Sarna SK. Nitric oxide modifies chromatin to suppress ICAM-1 expression during colonic inflammation. Am J Physiol Gastrointest Liver Physiol 303: G103-G110, 2012. First published April 19, 2012 doi:10.1152/ajpgi.00381.2011 is an established inflammatory mediator. However, it remains controversial whether NO enhances the inflammatory response in the colon or suppresses it. We investigated the epigenetic regulation of Icam-1 expression by NO following induction of colonic inflammation in rats by 2,4,6-trinitrobenzene sulfonic (TNBS) acid and obtaining colonic muscularis externae tissues 24 h later. TNBS inflammation induced intercellular adhesion molecule-1 (ICAM-1) expression by translocating NF-B to the nucleus. The incubation of inflamed tissues with S-nitrosoglutathione (GSNO) did not affect the nuclear translocation of NF-B; however, it suppressed the NF-B binding to DNA. Chromatin immunoprecipitation analysis (ChIP)-qPCR assays showed that the increase in NF-B/DNA interaction following inflammation is due to the transcriptional downregulation of global HDAC3 and a decrease in its interaction with the DNA on the Icam-1 promoter containing the binding motifs of NF-B. The decrease in the association of histone deacetylase (HDAC) 3 with the Icam-1 promoter increased the acetylation of histone 4 lysine residue 12 (H4K12), which would favor chromatin relaxation and greater access of NF-B to its DNA binding sites. HDAC3 dissociation from the DNA did not affect the acetylation levels of H4K8 and H4K16. The NO release by GSNO countered the upregulation of Icam-1 by increasing the transcription of global HDAC3 and its association with the Icam-1 promoter, and by suppressing H4K12 acetylation. We conclude that chromatin modification by transcriptional downregulation of HDAC3 plays a critical role in the induction of the inflammatory response. NO may serve as an anti-inflammatory mediator during the acute stage of inflammation by blunting the downregulation of global HDAC3, increasing HDAC3 interaction with the nucleosomes containing the binding moieties of NF-B, reducing H4K12Ac to restrict the access of NF-B to DNA, and suppressing ICAM-1 expression. intercellular adhesion molecule-1; inflammation NITRIC OXIDE (NO) and inducible NO synthase (iNOS) are elevated in the inflamed tissues of patients with ulcerative colitis and Crohn's disease (9, 32, 37) as well as in the tissues of rodent models of these diseases, dextran sodium sulfate (DSS)-and trinitrobenzene sulfonic acid (TNBS)-induced inflammation, respectively (15). These findings suggest that NO may serve as an inflammatory mediator in inflammatory bowel disease. However, experiments in intact animal models have been inconclusive. Some studies found that prophylactic or therapeutic inhibition of iNOS attenuates gut inflammation and injury, implying that NO is deleterious (10, 16, 28) . Other studies found that the blockade of iNOS by pharmacological inhibitors or knockout of the iNOS gene either has no effect or worsens the inflammatory response, suggesting that NO has a benign or beneficial role in inflammation (6, 11, 18, 26) . The cellular mechanisms by which NO may suppress or enhance the inflammatory response remain incompletely understood.
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The inflammatory response in intact animals is complex and involves numerous cell types and a multitude of pro-and anti-inflammatory mediators with varying time courses of expression and intensity of release. Most of the above studies investigated the potential role of iNOS-derived NO by administering iNOS antagonists in vivo at various acute or chronic stages of the inflammatory response (16, 18, 26, 28) , which may be one of the factors in divergent outcomes. In addition, studies in intact animals restrict the investigation of cellular and molecular mechanisms of pathology. We investigated the role of NO in TNBS-induced colonic inflammation in intact rats, obtaining muscularis externae tissues 24 h later to investigate cellular, molecular, and epigenetic mechanisms of the action of NO in regulating the expression of intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is a prominent mediator of inflammation, with greater expression throughout the thickness of the intestinal wall in Crohn's disease and ulcerative colitis patients (42) . ICAM-1 and other adhesion molecules express early in the inflammatory response to recruit immune cells. We investigated whether NO released by NO donor S-nitrosoglutathione (GSNO) alters the expression of ICAM-1 in inflamed tissues.
We tested the hypothesis that inflammation downregulates histone deacetylase-3 (HDAC3) mRNA and protein expression and its association with DNA to upregulate the acetylation of histone protein H4 on lysine residue 12 in the region of the Icam-1 promoter containing the binding motifs of NF-B. The resulting relaxation of the chromatin allows NF-B greater access to its binding moieties, resulting in increased Icam-1 mRNA and protein expression. We found that NO is an anti-inflammatory mediator that counters the transcriptional downregulation of global HDAC3, increases the association of HDAC3 with the Icam-1 promoter, and decreases H4K12Ac, which condenses the chromatin to restrict the access of NF-B to binding motifs on the Icam-1 promoter. NO does not affect the activation or translocation of NF-B to the nucleus.
CA) to construct all mutant Icam-1 promoter plasmids with mutant NF-B binding sites (site 1: Ϫ221/Ϫ209, TTTGGAAATTCCT vs. TTTGCTAATTCCT, mutant; site 2: Ϫ149/Ϫ137, CGGAAATAC-CGAA vs. CGCTAATACCGAA, mutant).
Animals. We used 6-wk-old male Sprague-Dawley rats purchased from Harlan Laboratories (Indianapolis, IN). The animals were fasted for 24 h with free access to GoLYTELY (Braintree Laboratories, Braintree, MA) to cleanse the colon before induction of inflammation with 65 mg/kg TNBS dissolved in saline containing 40% ethanol (vol/vol). Rats received isoflurane anesthesia for intracolonic administration of 250 l of TNBS/ethanol/saline solution injected 8 cm into the colon via a catheter. Holding the animals in a head-down position for 1 min prevented leakage of TNBS. Rats in the control group received saline. The rats were euthanized 24 h later to obtain tissues. The University of Texas Medical Branch Institutional Animal Care and Use Committee approved all procedures.
Preparation and treatment of rat colonic muscle externae tissues. Freshly obtained, full-thickness colon tissues were immersed in carbogenated Krebs solution with 5% O 2/95% CO2 mix (2) . The mucosal/submucosal layers were peeled off. The remaining muscularis externae tissues were placed in high glucose DMEM (HyClone, South Logan, UT) containing 10% FBS, antibiotics, and test reagents and incubated in a water-jacketed CO 2 incubator. For time course experiments, we incubated all specimens in the medium for the same duration and added the reagents at different time points. The treated tissues were snap-frozen in liquid nitrogen at the end of the whole incubation period. For example, GSNO was added 12, 6, and 1 h before harvesting for 12-, 6-, and 1-h time points, respectively. Samples at 0-h time point served as vehicle controls.
Cell culture, transient transfection, and luciferase assay. We used primary cultures of rat colonic circular smooth muscle cells (RCCSMC) in passage 2 or 3 for reporter assays. Transient transfection of Icam-1 reporter constructs, luciferase, and ␤-galactosidase (␤-Gal) assays were performed, as described previously (21, 22) .
Isolation of nuclear extracts and Western blot. We extracted cytoplasmic and nuclear extracts by using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific, Rockford, IL). We prepared whole cell lysates by using immunoprecipitation (IP) lysis buffer (22) . Western blotting was performed as described previously (22) . We used the following antibodies: anti-NF-B p65 rabbit polyclonal (Cell Signaling, Danvers, MA), anti-rat ICAM-1 monoclonal (R&D Systems), anti-histone H4 polyclonal and antihistone H4K8Ac (Millipore, Temecula, CA), anti-histone H4K12Ac, anti-histone H4K16Ac, and anti-HDAC3 rabbit polyclonal (Active Motif, Carlsbad, CA), anti-␣-tubulin and anti-histone H1 (Santa Cruz, CA), and anti-␤-actin mouse monoclonal (Sigma).
Oligonucleotide pulldown assay. Wild-type oligonucleotides no. 1 (5=-TTACTTCAGTTTGGAAATTCCTGGGTCGCAG-3=) and no. 2 (5=-GTCTCCATCCGGAAATACCGAAGCCCTCATT-3=) (NF-B binding motifs in bold), as well as mutant oligonucleotides no. 1 (5=-TTACTTCAGTTTGCTAATTCCTGGGTCGCAG-3=) and no. 2 (5=-GTCTCCATCCGCTAATACCGAAGCCCTCATT-3=) (mutated nucleotides underlined) were biotinylated and incubated with 50 g of nuclear extracts from rat colonic muscularis externae (22) . NF-B p65, precipitated by biotin-labeled oligos, was detected by immunoblotting.
HAT and HDAC assays. Colonic inflammation was induced by intracolonic administration of 17, 65, or 130 mg/kg TNBS dissolved in saline containing 40% ethanol (vol./vol.). Saline infusion served as vehicle control. Colonic muscle strips were collected 24 h later and snap-frozen in liquid nitrogen. Frozen tissues were smashed, and nuclear extracts were extracted by using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific). We measured HAT and HDAC activities in nuclear extracts by using the HAT Activity Colorimetric Kit and the Colorimetric HDAC Activity Assay Kit (BioVision, Mountain View, CA), respectively. Each reaction used 100 g of nuclear extract.
Chromatin immunoprecipitation-real-time PCR assay. We performed chromatin immunoprecipitation (ChIP) assays as described previously (22) . The rat Icam-1-specific primers (forward: 5=-CTTCTCTC-CCGGACTCTCCT-3=; reverse: 5=-GGAATGAGGGCTTCGGTATT-3=) covering the NF-B binding region (nt Ϫ290/Ϫ127) of the promoter and SYBR Green Master Mix (Applied Biosystems, Foster City, CA) were used for real-time PCR. We normalized fold differences in precipitated DNA against input.
Real-time RT-PCR. We extracted the total RNA by using RNeasy mini kit (QIAGEN, Valencia, CA). One microgram of total RNA was reverse-transcribed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). Quantification of Icam-1 and HDAC3 mRNA levels by real-time PCR was performed with a StepOnePlus Thermal Cycler and Taqman probe and primers (Applied Biosystems). 18S rRNA was quantified as an internal control for the amount and quality of cDNA. All samples were assayed in triplicate in an optical 96-well reaction plate with optical adhesive covers in a 20-l volume containing 7 l (2 l for 18S rRNA) diluted cDNA (1:5 dilution in water).
Statistics. We expressed all data as means Ϯ SE and used twotailed Student's t-test or one-way ANOVA followed by Fisher's post hoc analysis and considered P Ͻ 0.05 as significant.
RESULTS

GSNO suppresses inflammation-induced Icam-1 transcription in colonic muscularis externae. TNBS-induced inflamma-
tion significantly upregulated ICAM-1 protein and mRNA levels in the muscularis externae isolated from the rat colon at 24 h after the insult (Fig. 1, A and B) . The treatment of these tissues with the NO donor GSNO suppressed the increase in ICAM-1 protein (Fig. 1A ) and mRNA expression (Fig. 1B) in a concentration-dependent manner. GSNO treatment (25 M) took Ͻ6 h to suppress significantly the ICAM-1 protein expression in the above tissues (Fig. 1C) . In addition, in vitro incubation of colonic muscularis externae tissues from naive rats with 20 ng/ml IL-1␤ time-dependently upregulated ICAM-1 protein expression (Fig, 1D) , whereas co-incubation of tissues with GSNO blunted this increase (Fig. 1E) .
The roles of NF-B and HDAC inhibition in the transcription of Icam-1. Pro-inflammatory cytokines IL-1␤ and TNF-␣ induce the expression of Icam-1 in immune and nonimmune cells by activating the transcription factor NF-B, causing it to translocate to the nucleus (31, 36, 41, 43) . MatInspector software (Genomatrix, Germany) identified two NF-B binding motifs (Ϫ221/Ϫ209 and Ϫ149/Ϫ137) on the Icam-1 promoter, separated by 60 nucleotides (Fig. 2A) . We investigated whether one or both of these cis-elements mediate the transcription of Icam-1 in response to IL-1␤. We incubated nuclear extracts of the muscularis externae with biotinylated oligonucleotides containing each putative NF-B recognition sequence. Each sequence precipitated p65 NF-B (Fig. 2B ), but the upstream binding site showed higher affinity to p65 than the downstream site. Oligonucleotides containing mutant NF-B sites pulled down no p65.
Next, we used mutation analysis to investigate the relative roles of the two NF-B binding motifs in mediating transcription of Icam-1 in response to IL-1␤ or TSA, an established histone deacetylase (HDAC) inhibitor (29) (Fig. 2C, left) . We transiently transfected the rat Icam-1 promoter (Ϫ1,758/ϩ80)-pGL3-basic luciferase reporter constructs into primary cultures of RCCSMCs, with ␤-galactosidase (␤-Gal) as an internal control. Twenty-four hours later, we treated the transfected cells with 20 ng/ml IL-1␤ or 1 M TSA for another 24 h. TSA significantly suppressed the global HDAC activity (Fig. 2D ). Luciferase and ␤-Gal assays showed that both IL-1␤ and TSA significantly increase the wild-type Icam-1 promoter activity (Fig. 2C, right) . The increase in promoter activity induced by TSA was sixfold greater than that induced by IL-1␤. Mutation of the upstream NF-B recognition site completely abolished the basal Icam-1 promoter activity as well as its induction by NO does not affect the translocation of NF-B to the nucleus. We investigated whether NO suppresses the expression of Icam-1 by blocking the translocation of NF-B to the nucleus. ChIP-qPCR assays with anti-p65 antibody and primers specific to the rat Icam-1 promoter region containing both NF-B binding moieties (Ϫ290/Ϫ127) showed that TNBS insult significantly increases the binding of p65 to the Icam-1 promoter at 24 h post-inflammation (Fig. 3A, second column) . The incubation of inflamed muscularis externae tissues with 25 M GSNO for 12 h significantly reduced this binding (Fig.  3A) . The separation of nuclear fractions followed by Western blotting showed that inflammation significantly increased nuclear p65 (Fig. 3B) ; co-incubation with GSNO did not affect this increase, suggesting that NO does not affect the translocation of p65 NF-B to the nucleus. The absence of ␣-tubulin, a cytoplasmic marker, and the clear presence of histone H1, a nuclear marker, established the clean separation of nuclear fractions from cytoplasmic proteins (Fig. 3B) .
Competitive modification of chromatin containing NF-B binding motifs by inflammation and NO in the regulation of
Icam-1 expression. Histone acetylation and deacetylation play critical roles in regulating gene transcription (7, 23, 44) . The acetylation of lysine residues at histone NH 2 -terminal tails relaxes the chromatin to allow transcription factors greater access to their binding motifs and to enhance transcription; deacetylation does the opposite. We investigated whether NO modulates the acetylation of H4 lysine residues 8, 12, and 16 associated with the nucleosomes containing the recognition sequences of p65 NF-B to suppress Icam-1 transcription by TNBS inflammation. Western blotting for H4K8Ac, H4K12Ac, and H4K16Ac showed significant global increases in all three acetylated lysine residues, whereas total histone H4 protein remained unchanged (Fig. 4, A-C) . The acetylation of histone proteins at the lysine residues of NH 2 -terminal tails is gene and sequence specific. ChIP-qPCR assays showed that TNBS inflammation significantly increases the amount of H4K12Ac in the nucleosomes containing the two NF-B binding moieties without affecting the acetylation of H4K8 and H4K16 (data not shown). NO released by GSNO significantly suppressed the acetylation of H4K12 (Fig. 4D ) but had no significant effect on the acetylation levels of H4K8 and H4K16 (data not shown).
Inflammation suppresses and NO enhances HDAC3 transcription to regulate acetylation of H4K12 and Icam-1 transcription.
HAT and HDAC assays showed that TNBS inflammation reduces the total activity of HATs in a dose-dependent manner (Fig. 5A ) but has no effect on global HDAC activity ( Fig. 5B ) in nuclear extracts of colonic muscularis externae at 24 h after insult. These data suggest that the increase in acetylation of lysine residues on histone H4 may be due to suppression of specific HDACs. HAT activity did not increase; therefore, it is Fig. 3 . GSNO attenuates NF-B p65 binding to the rat Icam-1 promoter without affecting nuclear p65 protein levels. A: TNBSinduced inflammation augmented NF-B p65 association with the Icam-1 promoter; 25 M GSNO abrogated the increase in binding in rat colonic muscularis externae. Chromatin immunoprecipitation (ChIP) assays followed by realtime PCR assessed p65/Icam-1 promoter interaction. Rabbit IgG was used for mock precipitation. N ϭ 3. *Significant difference vs. Ctr (P Ͻ 0.05). # Significant difference vs. value at 24 h after TNBS insult (P Ͻ 0.05). B: GSNO had no effect on the increase of nuclear p65 by inflammation. Cytoplasmic marker ␣-tubulin and nuclear marker histone H1 showed clean separation of cytoplasmic and nuclear fractions. unlikely to contribute to the increase in acetylation of lysine residues. We found that the colonic muscularis externae tissues express HDAC3 (Fig. 6A ) and low levels of HDAC4 and HDAC1 (Fig. 6, C and D) . Therefore, we investigated whether inflammation and NO both target HDAC3 in regulating ICAM-1 expression. Western blots and real-time RT-PCR showed that TNBS inflammation significantly suppressed both HDAC3 protein and mRNA (Fig. 6, A and B, respectively) . HDAC1 also decreased significantly, but the decrease in HDAC4 was not significant (Fig. 6, C and D) . The treatment of colonic muscularis externae tissues from TNBS rats with GSNO significantly reversed the suppression of HDAC3 by TNBS inflammation in under 6 h ( Fig. 6B ) but had no effect on HDAC1 and HDAC4 (data not shown). Earlier, we showed in Fig. 1B that GSNO treatment in the inflamed tissues suppressed the expression of ICAM-1, also within 6 h.
ChIP-qPCR assays showed that TNBS inflammation significantly suppressed the association of HDAC3 with the Icam-1 promoter region containing the NF-B binding moieties; GSNO treatment reversed this suppression (Fig. 6E) . Together, these findings suggest that the suppression of HDAC3 may play a key role in the TNBS-induced increase in the expression of ICAM-1 in colonic inflammation; NO counters this increase by upregulating the expression of HDAC3. In vitro experiments also showed that HDAC3 suppression occurs via transcriptional downregulation or increased mRNA turnover. The in vitro incubation of naive muscularis externae tissues with IL-1␤ significantly suppressed HDAC3 mRNA; treatment with GSNO concentration-dependently reversed this suppression (Fig. 6F) .
We confirmed the role of increased acetylation of H4K12 in enhancing the binding of p65 NF-B to DNA by treating muscularis externae tissues from naive rats with 1 M TSA. TSA markedly upregulated ICAM-1 protein expression and the global acetylation of H4K8, H4K12, and H4K16 (Fig. 7A) . ChIP-qPCR assays showed that TSA significantly reduced the association of HDAC3 with the Ϫ290/Ϫ127 region of Icam-1 promoter containing the binding moieties of NF-B, which enhanced the acetylation of H4K8, H4K12, and H4k16 in this segment of the promoter (Fig. 7B) . TSA also enhanced the binding of p65 NF-B to its binding moieties (Fig. 7B) , indicating that histone H4 hyperacetylation relaxes the nucleosomes containing NF-B binding domains and hence increases the accessibility of NF-B to the rat Icam-1 promoter. Note that inflammation increased H4K12Ac only, whereas nonselective HDAC inhibitor increased H4K8Ac and H4K16Ac as well, which explains the greater increase in Icam-1 promoterreporter activity initiated by TSA over that of IL-1␤ (Fig. 2C) .
DISCUSSION
The transcription factor NF-B is a key regulator of inflammation. In response to the activation of membrane receptors of proinflammatory mediators, NF-B translocates to the nucleus. However, nuclear translocation by itself does not induce transcription of target genes. Chromatin modification is the next level that regulates the access of the NF-B complex to its cognate sequences on the promoters of genes involved in the inflammatory response (19, 33) . The addition/removal of acetyl groups to lysine residues on the NH 2 -terminal tails of histone proteins is the most understood mechanism of regulation of DNA/histone interaction. Our findings show that colonic inflammation has no effect on global HDAC activity, but it significantly downregulates HDAC3 protein expression in colonic muscularis externae. By contrast, global HDAC activity increases in the tissues of several types of cancers (1), decreasing the transcription rates of multiple susceptible genes, specifically tumor suppressor genes promoting apoptosis. HDAC inhibitors are in clinical trials or are approved by FDA for treatment of cancer (25) . Treating colonic inflammation with HDAC inhibitors would be counterproductive because HDAC3 is already suppressed.
HDACs, expressed in all mammalian tissues, play critical roles in differentiation, growth, and homeostasis (46) . Our understanding of HDACs is still evolving. According to a recent classification, mammalian HDACs fall into one of four classes depending on their structure and amino acid sequence (5, 8, 46) . Class I (HDAC1-3 and 8) HDACs are TSA sensitive and reside predominantly in the nucleus; mammalian tissues express these ubiquitously. Class II (HDAC4 -7, and 9) and class IV (HDAC10) HDACs are tissue specific, TSA sensitive, and may be found in both the cytoplasm and the nucleus; they undergo stimulus-dependent nucleo-cytoplasmic shuttling. Class III (SIRT1-7) HDACs belong to the sirtuins family; they are insensitive to TSA and can be found in the nucleus, cytoplasm, and mitochondria (27) . We found that the muscularis externae tissues express HDAC3 in both the cytoplasm and the nucleus. TNBS inflammation reduced the expression of HDAC3 and the association of HDAC3 with the nucleosomes containing the NK-B binding sequences on the Icam-1 promoter. The HDACs do not have an intrinsic affinity for DNA; multi-protein complexes comprised of the corepressors silencing mediator of retinoic and thyroid receptors (SMRT) and nuclear receptor corepressor (N-CoR) recruit them to the DNA (20) . However, the mechanisms of action of NO on HDACs depend on their cellular location and on the intracellular concentration of NO. In human umbilical vein endothelial cells, NO inhibits serum-induced histone acetylation by enhancing the activity of cytoplasmic class II HDACs 5 and 6 and shuttling them to the nucleus (12) . Class I HDACs are not involved in this effect. In vitro findings in cultures of rat cortical neurons showed that brain-derived neurotrophic factor (BDNF)-dependent generation of low nanomolar concentration of NO (catalyzed by neuronal NOS) S-nitrosylates HDAC2 at residues Cys 262 and Cys 274 dissociate it from the chromatin and facilitate the acetylation of histones H3 and H4 (30) . Our findings show that high micromolar concentration of NO, catalyzed by iNOS, in TNBS inflammation upregulates the transcription of HDAC3 to increase its association with the Icam-1 promoter and suppress the transcription of Icam-1.
Our findings suggest that NO release at the onset of inflammatory response, when the immune and nonimmune cells express ICAM-1 to recruit leukocytes, serves as an early anti-inflammatory mediator; the incubation of inflamed tissues with GSNO, 24 h after inflammatory insult, suppressed ICAM-1 expression. However, it is noteworthy that ICAM-1 is only one of the several adhesion molecules that together regulate the trafficking of leukocytes. The epigenetic regulation is gene specific. We did not investigate whether NO also blocks the expression of other adhesion molecules or other inflammatory mediators. The inhibition of ICAM-1 by itself may have a limited effect on the overall inflammatory response (45) . In addition, ICAM-1 inhibition has little effect on inflammation once it is past the initial stage of leukocyte recruitment. This may explain the lack of effect of iNOS inhibitors administered during the chronic stage of inflammation (11, 34) . Perhaps for these reasons, the neutralization of ICAM-1 or inhibition of its synthesis in established Crohn's disease, rheumatoid arthritis, acute kidney allograft, and cerebral stroke patients has not yielded promising outcomes (14, 24, 35, 45) .
In vitro studies using cell cultures of human vascular endothelial cells reported that NO inhibits the proinflammatory cytokine-induced translocation of p65 NF-B to the nucleus by stabilizing IB-␣ in the cytoplasm (4, 38) . Our findings in intact ex vivo muscularis externae tissues show that NO does not affect the translocation of NF-B to the nucleus in TNBSinduced inflammation. It enhances the transcription of HDAC3 and its association with the nucleosomes containing the NF-B binding moieties, which reduces the acetylation level of H4K12 to suppress the expression of Icam-1. The biological effects of NO appear to be tissue and environment specific.
HDAC3 causes strong deacetylation of H2A, H4K5, and H4K12 but only partial deacetylation of H3, H2B, H4K8Ac, and H4K16Ac (13) . The acetylated lysine 12 of histone H4 is one of the active marks of euchromatin. The bromodomain protein Brd2 selectively interacts with H4K12Ac during mitosis and leads to transcriptional activation in culture cells (17, 40) . We found that increased transcription of HDAC3 by NO strongly suppresses H4K12Ac, while showing much weaker effects on H4K8Ac and H4K16Ac. Likewise, the decrease in the expression of HDAC3 in response to inflammation or IL-1␤ increased H4K12Ac but not H4K8Ac and H4K16Ac in the same segment of chromatin. RNAi-induced reduction of HDAC3 in SW480 colorectal cancer cells also leads to increased histone H4K12 acetylation but not acetylation of K5, K8, or K16 (39) . Taken together, these results indicate that H4K12 appears to be a strong substrate of HDAC3 in colonic muscularis externae. However, chromatin modification is stimulus, cell, and gene segment specific.
In conclusion, chromatin modification plays a critical role in the induction of the inflammatory response in the muscularis externae of the colon. During the acute stage of inflammation, the proinflammatory mediators activate and translocate NF-B to the nucleus. At the same time, these mediators transcriptionally downregulate the expression of HDAC3, which leads to its dissociation from the nucleosomes containing the binding moieties of NF-B on the Icam-1 promoter. The decrease in HDAC3 was accompanied by increase in the acetylation of H4K12 followed by increase in the binding of nuclear NF-B to its DNA recognition sequences on the Icam-1 promoter, which may reflect the known role of H4K12 acetylation in chromatin relaxation (3) . Our data show that NO acts as an anti-inflammatory mediator; it upregulates the transcription of HDAC3 to suppress the acetylation of H4K12, which results in chromatin compaction, a decrease in the binding of NK-B to the Icam-1 promoter, and suppression of ICAM-1.
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